Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab

Nivolumab is an immune checkpoint inhibitor that is used to treat various advanced cancers, including metastatic non-small cell lung cancer (NSCLC). Nivolumab treatment has different side effects. For this patient with advanced NSCLC, pericardial effusion was considered to be an immune-related adver...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Zhihui, Yao, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425282/
https://www.ncbi.nlm.nih.gov/pubmed/32780611
http://dx.doi.org/10.1177/0300060520937490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425282/
https://www.ncbi.nlm.nih.gov/pubmed/32780611
http://dx.doi.org/10.1177/0300060520937490

Ejemplares similares